Skip to content
Review

Porous Framework Materials and MXenes as Biosensing Platforms for Amyloid-β Detection.

Sep 2026 · The chemical record · pp. e70253 · 0 citations · 87 references
Medicine

TL;DR

Recent advances in Aβ biosensors based on metal-organic frameworks, covalent organic frameworks, hydrogen-bonded organic frameworks, and MXenes are summarized, with emphasis on comparative analytical performance across electrochemical, optical, photoelectrochemical, and dual-mode platforms.

Abstract

Amyloid-β (Aβ), a 39-43-amino-acid peptide, is closely associated with the pathogenesis of Alzheimer's disease (AD) and undergoes abnormal aggregation that contributes to disease progression. Therefore, rapid and accurate Aβ detection is essential for early AD diagnosis and therapeutic monitoring. Biosensors have emerged as promising analytical tools owing to their simplicity, low cost, high sensitivity, and selectivity. In particular, metal-organic frameworks, covalent organic frameworks, hydrogen-bonded organic frameworks, and MXenes offer unique structural and functional advantages for Aβ sensing. This review summarizes recent advances in Aβ biosensors based on these materials, with emphasis on comparative analytical performance across electrochemical, optical, photoelectrochemical, and dual-mode platforms. Current challenges, including matrix interference, limited discrimination of Aβ isoforms, and biosensor miniaturization, are discussed. Future directions involving artificial intelligence and machine learning are also highlighted to advance rapid, sensitive, and accurate Aβ detection for early AD diagnosis and therapeutic monitoring.

View source

Similar papers

Review 2026

Advances in nanomaterial-based biomarker detection for neurodegenerative diseases: Special focus on Alzheimer's and Parkinson's disease.

A review examines the potential of nanomaterial-based sensing strategies for developing clinically relevant neurodiagnostics, categorizes them systematically, and links them to biomarker profiles for AD and PD.

Shajahan Azeez, Raj Kumar Chinnadurai, Saravanaraman Ponne et al. · 0 citations
Review Open access Sep 2026

Colorimetric gold nanosensors for monitoring protein aggregation: implications for Alzheimer's disease.

The design and engineering of gold-nanomaterial-based colorimetric biosensors for monitoring protein aggregation are presented and the current challenges and emerging opportunities for applying these nanosensors to combat AD are highlighted.

Célia Sahli, Haining Zhu, Kenry · 0 citations
Review Sep 2026

DNA- and aptamer-based biosensors for Alzheimer's disease biomarkers toward clinical translation.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which early diagnosis remains a major challenge. DNA-based biosensors and aptamer-based biosensors have emerged as complementary platforms for the sensitive and selective detection of Alzheimer's disease biomarkers. DNA biosensors primarily detect...

Y. Pahlavan, Mehran Nozari-Asbemarz, Mojtaba Amani et al. · 0 citations
Review Open access Sep 2026

Miniaturized biosensor platforms for early detection of neurodegenerative diseases and their potential for clinical translation

Neurodegenerative disorders (NDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and prion diseases, are defined by the gradual deterioration of neurons that frequently occurs prior to the onset of clinically observable symptoms. The early diagnosis of these conditions relies on analytical systems that ar...

İnci Uludağ Anıl, Buse Sancakli, Nicole Jaffrezic-Renault et al. · 0 citations
Sep 2026

Affinity peptide-based microfluidic electrochemical system for ultrasensitive detection of amyloid-β peptides.

In serum samples, the μF-APEC system showed strong agreement with conventional enzyme-linked immunosorbent assay measurements and clearly distinguished AD patients from healthy individuals, demonstrating its potential for the early screening of AD.

Ang-Yang Shang, Zhi-Qi Zhang, Jing-Yuan Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.